{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:25:29Z","timestamp":1790889929537,"version":"4.1.0"},"reference-count":16,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,10,31]],"date-time":"2006-10-31T00:00:00Z","timestamp":1162252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2007,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We sought to assess the short\u2010term clinical effects of tetrabenazine (TBZ) on choreic movements in Huntington's disease patients. A total of 10 patients on stable doses of TBZ were enrolled in this observational study. Patients took their evening dose of TBZ and presented the next day to the Baylor College of Medicine Movement Disorders Clinic without taking the usual morning dose. They were assessed using the Unified Huntington's Disease Rating Scale (UHDRS) motor assessment and Beck Depression Inventory. The usual morning dose of TBZ was then administered and patients were followed with serial UHDRS motor examinations approximately every 2 hours until choreic movements subsided and then returned. TBZ decreased the UHDRS chorea score on average 42.4% \u00b1 17.8%. The duration of effect varied from a minimum of 3.2 hours to a maximum of 8.1 hours (mean = 5.4 \u00b1 1.3). No patient experienced an adverse event related to TBZ or its withdrawal. During short\u2010term follow\u2010up after a single dose, TBZ improves chorea for approximately 5 hours. \u00a9 2006 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.21161","type":"journal-article","created":{"date-parts":[[2006,10,31]],"date-time":"2006-10-31T15:52:01Z","timestamp":1162309921000},"page":"10-13","source":"Crossref","is-referenced-by-count":51,"title":["Short\u2010term effects of tetrabenazine on chorea associated with Huntington's disease"],"prefix":"10.1002","volume":"22","author":[{"given":"Christopher","family":"Kenney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,1,22]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(84)90562-4"},{"key":"e_1_2_6_3_2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0022-3565(25)25665-8","article-title":"Biochemical and pharmacological studies of RO 1\u20109569 (tetrabenazine), a nonindole tranquilizing agent with reserpine\u2010like effects","volume":"127","author":"Quinn GP","year":"1959","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1986.tb04506.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnf.0000136892.24629.96"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.6.1.7"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000198586.85250.13"},{"key":"e_1_2_6_8_2","first-page":"1244","article-title":"A randomized, double\u2010blind, placebo\u2010controlled, staggered withdrawal study in patients with Huntington's disease treated with tetrabenazine","volume":"20","author":"Frank S","year":"2005","journal-title":"Ann Neurol"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200211000-00003"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.2.358"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10427"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(66)90031-1"},{"key":"e_1_2_6_13_2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0090-9556(25)06690-5","article-title":"Pharmacokinetics of tetrabenazine and its major metabolite in man and rat: bioavailability and dose dependency studies","volume":"15","author":"Mehvar R","year":"1987","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00615962"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.5.1067"},{"key":"e_1_2_6_16_2","first-page":"2252","article-title":"In vivo imaging of the brain vesicular monoamine transporter","volume":"36","author":"Vander Borght TM","year":"1995","journal-title":"J Nucl Med"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1993.tb03521.x"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.21161","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.21161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:58:54Z","timestamp":1760968734000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.21161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["10.1002\/mds.21161"],"URL":"https:\/\/doi.org\/10.1002\/mds.21161","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}